NZ553688A - Enzyme inhibitors for the inhibition of insulin-regulated aminopeptidase - Google Patents

Enzyme inhibitors for the inhibition of insulin-regulated aminopeptidase

Info

Publication number
NZ553688A
NZ553688A NZ553688A NZ55368805A NZ553688A NZ 553688 A NZ553688 A NZ 553688A NZ 553688 A NZ553688 A NZ 553688A NZ 55368805 A NZ55368805 A NZ 55368805A NZ 553688 A NZ553688 A NZ 553688A
Authority
NZ
New Zealand
Prior art keywords
alkyl
use according
optionally substituted
aryl
heteroaryl
Prior art date
Application number
NZ553688A
Other languages
English (en)
Inventor
Siew Yeen Chai
Michael William Parker
Anthony Lloyd Albiston
Craig J Morton
Hooi Ling Ng
Siying Ye
Frederick A O Mendelsohn
Original Assignee
Florey Howard Inst
St Vincents Inst Med Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004905182A external-priority patent/AU2004905182A0/en
Application filed by Florey Howard Inst, St Vincents Inst Med Res filed Critical Florey Howard Inst
Publication of NZ553688A publication Critical patent/NZ553688A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
NZ553688A 2004-09-09 2005-09-09 Enzyme inhibitors for the inhibition of insulin-regulated aminopeptidase NZ553688A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004905182A AU2004905182A0 (en) 2004-09-09 Enzyme inhibitors and uses thereof
PCT/AU2005/001380 WO2006026832A1 (en) 2004-09-09 2005-09-09 Enzyme inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
NZ553688A true NZ553688A (en) 2011-05-27

Family

ID=36036029

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ553688A NZ553688A (en) 2004-09-09 2005-09-09 Enzyme inhibitors for the inhibition of insulin-regulated aminopeptidase

Country Status (13)

Country Link
US (1) US20080194636A1 (https=)
EP (1) EP1789079B1 (https=)
JP (1) JP5031567B2 (https=)
KR (1) KR20070100878A (https=)
CN (1) CN101039690A (https=)
CA (1) CA2579768A1 (https=)
DK (1) DK1789079T3 (https=)
ES (1) ES2403340T3 (https=)
IL (1) IL181819A (https=)
NZ (1) NZ553688A (https=)
SG (1) SG155901A1 (https=)
WO (1) WO2006026832A1 (https=)
ZA (1) ZA200702041B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009065169A1 (en) 2007-11-19 2009-05-28 Howard Florey Institute Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof
CN101284820B (zh) * 2008-04-25 2011-05-04 南昌大学 一种氨肽酶抑制剂及合成方法
CN103848805A (zh) * 2012-12-06 2014-06-11 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103896900A (zh) * 2012-12-25 2014-07-02 韩冰 一类具有神经保护作用的化合物及其制备方法和用途
MX373831B (es) 2014-05-28 2020-03-25 Astellas Pharma Inc Derivado de piridina.
AR102849A1 (es) 2015-03-09 2017-03-29 Astellas Pharma Inc Compuesto de piridina bicíclica
CA3017028C (en) 2015-07-30 2020-06-16 Monash University Fibrotic treatment
EP4440570A1 (en) 2021-12-01 2024-10-09 Institut National de la Santé et de la Recherche Médicale (INSERM) Irap inhibitors for use in the treatment of inflammatory diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284868A (en) * 1991-10-09 1994-02-08 Eli Lilly And Company Pharmaceutical compounds
US5281619A (en) 1992-09-25 1994-01-25 Eli Lilly And Company Therapy for diabetic complications
EP1004584A3 (en) 1992-11-18 2000-07-05 Eli Lilly And Company Limited Pyranoquinoline derivatives as inhibitors of cell proliferation
US6680332B1 (en) * 1999-06-04 2004-01-20 Euro-Celtique S.A. Substituted 5-oxo-5,6,7,8-tetrahydro-4H-1-benzopyrans and benzothiopyrans and the use thereof as potentiators of AMPA
US7053117B2 (en) * 2001-05-16 2006-05-30 Cytovia, Inc. Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2003011304A1 (en) * 2001-08-02 2003-02-13 Howard Florey Institute Of Experimental Physiology And Medicine Modulation of insulin-regulated aminopeptidase (irap)/angiotensin iv (at4) receptor activity
US20030114418A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor
ES2252656T3 (es) * 2002-02-13 2006-05-16 F. Hoffmann-La Roche Ag Nuevos derivados de piridina y quinolina.
WO2009065169A1 (en) * 2007-11-19 2009-05-28 Howard Florey Institute Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof

Also Published As

Publication number Publication date
IL181819A0 (en) 2007-07-04
EP1789079A4 (en) 2010-09-01
ZA200702041B (en) 2008-09-25
EP1789079B1 (en) 2012-11-07
SG155901A1 (en) 2009-10-29
JP2008512395A (ja) 2008-04-24
DK1789079T3 (da) 2013-03-11
US20080194636A1 (en) 2008-08-14
KR20070100878A (ko) 2007-10-12
WO2006026832A1 (en) 2006-03-16
EP1789079A1 (en) 2007-05-30
ES2403340T3 (es) 2013-05-17
JP5031567B2 (ja) 2012-09-19
CA2579768A1 (en) 2006-03-16
CN101039690A (zh) 2007-09-19
IL181819A (en) 2013-07-31

Similar Documents

Publication Publication Date Title
US8377963B2 (en) Insulin-regulated aminopeptidase (IRAP) inhibitors and uses thereof
WO2008046155A1 (en) Methods for regulating glucose homeostasis and agents therefor
JP7457360B2 (ja) 線維症の処置
Kehr et al. Microdialysis in freely moving mice: determination of acetylcholine, serotonin and noradrenaline release in galanin transgenic mice
Klassen et al. Age-dependent diastolic heart failure in an in vivo Drosophila model
EP1789079B1 (en) Insulin-regulated aminopeptidase (IRAP) inhibitors and uses thereof
US20220127226A1 (en) Anti-arrhythmicity agents
JP4590397B2 (ja) ＰＴＥＮ阻害剤またはＭａｘｉ−Ｋチャンネルオープナー
AU2005282229B2 (en) Enzyme inhibitors and uses thereof
WO2016179645A1 (en) 4h-pyran compounds as insulin-regulated aminopeptidase (irap) inhibitors
CN110721307A (zh) 神经调节蛋白1在制备增强trpc6通道活性产品中的应用
Ferraro et al. The new compound GET73, N-[(4-trifluoromethyl) benzyl] 4-methoxybutyramide, Regulates hippocampal Aminoacidergic transmission possibly via an allosteric modulation of mGlu5 receptor. Behavioural evidence of its “anti-alcohol” and anxiolytic properties
AU2007234577A1 (en) Novel compounds and uses thereof
US20090010909A1 (en) Novel GPCR and methods of use of the same
CA2611072A1 (en) Novel compounds and uses thereof
JP2022554159A (ja) Ｇａｂａａ受容体モジュレーターによるてんかん状態の治療
JP2017518333A (ja) 神経系の変性疾患を治療及び予防するためのｐ３８及びｊｎｋ ｍａｐｋ阻害剤
Swaroop The Dopaminergic Cell-Intrinsic Clock and Bidirectional Relationships of Circadian Disruption and Synucleinopathy

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed